泰国儿童中应用日本脑炎减毒活重组疫苗的上市后IV期安全性研究
该项在泰国开展的前瞻性IV期开放标签多中心安全性研究,于2013年11月至2015年4月为10,000名9月龄至<5岁健康儿童接种日本脑炎减毒活重组疫苗(JE-CV),分为基础免疫组(第1组)和加强免疫组(第2组)。接种后60天内,第1组204名(3.0%)和第2组59名(1.9%)受试者报告严重不良事件(SAE),263名受试者共发生294例SAE,其中仅2名受试者的3例事件被认为与接种相关,均为中度荨麻疹。研究未发现JE-CV新的安全性问题,证实其良好的安全性特征。
要点
- 第1组SAE报告率为3.0%(204例),第2组为1.9%(59例),263名受试者共发生294例SAE。
- 仅2名受试者的3例事件被认为与接种相关,均为中度荨麻疹,无一符合超敏反应特别关注不良事件定义。
- 第1组特别关注不良事件28例(0.4%),第2组4例(0.1%),均与接种无关;热性惊厥最常见,第1组25例(0.4%),第2组2例(<0.1%)。
核心结论
- 研究未发现JE-CV新的安全性问题,并证实其良好的安全性特征。
研究设计与样本
- 前瞻性、IV期、开放标签、多中心安全性研究,于2013年11月至2015年4月在泰国开展,纳入10,000名9月龄至<5岁健康儿童。
- 受试者分为基础免疫组(第1组)和加强免疫组(第2组),接种JE-CV,评估接种后60天内的SAE(包括特别关注不良事件)及接种后30分钟内的即时3级全身性不良事件。
主要发现
- 受试者中位年龄第1组为1.1岁,第2组为3.8岁。
- SAE报告率第1组为3.0%(204例),第2组为1.9%(59例);263名受试者共发生294例SAE。
- 仅2名受试者的3例事件被认为与接种相关,均为中度荨麻疹,无一符合超敏反应特别关注不良事件定义。
- 特别关注不良事件第1组28例(0.4%),第2组4例(0.1%),均与接种无关;热性惊厥为最常见特别关注不良事件,第1组25例(0.4%),第2组2例(<0.1%)。
- 未报告日本脑炎病例,任何JE-CV接种后均未报告3级即时全身性不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Japanese encephalitis is a mosquito-borne viral disease endemic in most countries in Asia. A recombinant live, attenuated Japanese encephalitis virus vaccine, JE-CV, is licensed in 14 countries, including Thailand, for the prevention of Japanese encephalitis in adults and children. METHODS: This was a prospective, phase IV, open-label, multicentre, safety study of JE-CV conducted from November 2013 to April 2015, to evaluate rare serious adverse events (AEs). JE-CV was administered to 10,000 healthy children aged 9months to <5years in Thailand as a primary (Group 1) or booster (Group 2) vaccination. Serious AEs (SAEs), including AEs of special interest, up to 60days after administration were evaluated. Immediate Grade 3 systemic AEs up to 30min after JE-CV administration were also described. RESULTS: The median age of participants was 1.1years in Group 1 and 3.8years in Group 2. SAEs were reported in 204 (3.0%) participants in Group 1 and 59 (1.9%) participants in Group 2. Among a total of 294 SAEs in 263 participants, only three events occurring in two participants were considered related to vaccination. All three cases were moderate urticaria, none of which met the definition of AEs of special interest for hypersensitivity. AEs of special interest were reported in 28 (0.4%) participants in Group 1 and 4 (0.1%) participants in Group 2; none were considered related to vaccination. Febrile convulsion was the most frequently reported AE of special interest: 25 (0.4%) participants in Group 1; and 2 (<0.1%) in Group 2. There were no cases of Japanese encephalitis reported. No Grade 3 immediate systemic AEs were reported after any JE-CV vaccination. CONCLUSIONS: Our study did not identify any new safety concerns with JE-CV and confirms its good safety profile. This study was registered on www.clinicaltrials.gov (NCT01981967; Universal Trial Number: U1111-1127-7052).
引用
- Chotpitayasunondh T, Pruekprasert P, Puthanakit T, et al. Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand. Vaccine. 2016. PMID: 27903416. doi:10.1016/j.vaccine.2016.11.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。